Zn-Fe primary battery-enabled controlled hydrogen release in stomach for improving insulin resistance in obesity-associated type 2 diabetes.

ABSTRACT: Chronic systemic inflammation in obesity-associated type 2 diabetes (T2D) is a key inducing factor of insulin resistance (IR). Hydrogen molecule (H₂) has been proved to be a safe and effective anti-inflammatory agent, but conventional H₂ administration methods cannot provide a high dosage and a long duration of H₂ treatment in IR-related tissues and thus lead to limited therapeutic efficacies. We here propose a new strategy of controlled H₂ release to match the time window of gastric emptying for maximizing the bioavailability and therapeutic outcome of H₂. This work enhances the hydrolysis rate of Zn by constructing a Zn-Fe primary-battery micro-/nano-structure, and the H₂-releasing rate is adjusted by tuning the ratio of Z

SUBMITTER: Liu B 

PROVIDER: S-EPMC10689207 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature